by Öner Tulum, William Lazonick, and Ken Jacobson Despite vaccines’ significant public-health benefits, sales of all vaccines accounted for less than four percent of $872 billion in prescription-drug…
Blog Series
#1. Is there enough production capacity available for the vaccine supply to meet urgent demand in 2021?
by Öner Tulum, William Lazonick, and Ken Jacobson As COVID-19 vaccines receive regulatory approval, the world has a powerful weapon to fight the coronavirus. But at what pace…
